| 1. |
New concept suggests link between antibacterial dosing and resistance |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Tegaserod improves QOL, cost effective in IBS |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 3-3
&NA;,
Preview
|
|
摘要:
Irritable bowel syndrome (IBS) is a chronic, recurring disease affecting 10−20% of the US population. It is a multifaceted disorder, the exact cause of which is unknown, and is characterised by abdominal pain or discomfort, bloating and abnormal bowel function, resulting in chronic episodes of diarrhoea, constipation, or both in alternation. The burden of IBS on an individual can range from a mild inconvenience to severe debilitation, compounded by its unpredictability. As such, the disorder can have a broad and significant effect on patients' quality of life (QOL), controlling many aspects of their emotional, social and professional life. There is no known cure for IBS, and effective therapy remains a challenge. However, as the prevalence and impact of IBS becomes more well known, the medical community looks to new types of treatments for the disorder. Tegaserod [Zelnorm; Novartis], an indole carboxaldehyde derivative, is a selective serotonin4receptor partial agonist which targets receptors located throughout the GI tract. The agent is approved for use among patients with IBS whose primary bowel symptom is constipation, and has been shown in clinical trials to provide significant improvement in global IBS symptoms, and to be generally well tolerated. The effect of tegaserod on IBS patients' QOL, and the cost effectiveness of the drug, were assessed in two studies presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Hamburg, Germany; October 2004]. Both the studies were funded by Novartis, with which some of the researchers were affiliated.
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
New clinical guidelines on the use of androgens to treat female sexual dysfunction have been called for |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
The use of antidepressants is likely to decrease markedly in the UK following the release of new guidelines from the National Institute for Clinical Excellence |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
PEG 3350 worth it for idiopathic constipation in Belgium |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Findings from a survey conducted in the US suggest that asthma control among children and adolescents continues to fall short of national treatment goals. |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Greater drug consumption plumps up costs in obesity |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Guideline-concordant therapy lowers 30-day mortality in CAP |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Symptom, QOL benefits following insulin glargine in clinical practice |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Demand for cosmeceuticals in the US boosts market |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 468,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
